Literature DB >> 22810485

Continuous measurement of the cumulative amplitude and duration of hyperglycemia best predicts outcome after traumatic brain injury.

Qiang Yuan1, Hua Liu, Yang Xu, Xing Wu, Yirui Sun, Jin Hu.   

Abstract

BACKGROUND: This study aimed to assess the accuracy and utility of high-resolution continuous glucose recording in patients with traumatic brain injury (TBI) and to establish whether a relationship exists between the cumulative amplitude and duration of hyperglycemia and outcome after TBI.
METHODS: Glucose data for 56 TBI patients were collected continuously at 5-min intervals. The degree and duration of hyperglycemia above treatment thresholds were calculated as "glucose times time dose" (GTD; mg/dL d) using continuous recordings (GTD) for early stage (first 3 days). Long-term neurological functional outcome was assessed using the extended Glasgow Outcome Scale (GOSE). Receiver operating characteristic (ROC) curves were constructed to determine the predictive values of GTD, percentage readings, mean, and range of glucose for in-hospital mortality and GOSE.
RESULTS: All measurements of GTD were statistically significantly higher in the group that died. GTD of glucose >150 and glucose >180 had a high-predictive power for in-hospital mortality (areas under the ROC curve [AUC] = 0.917; 95 % CI, 0.837-0.998 and 0.876; 95 % CI, 0.784-0.967, respectively) and demonstrated significantly higher predictive power for mortality when compared with %reading >150 and %reading >180, respectively (p < 0.05). GTD of glucose >150 also had a significantly higher predictive power for mortality than mean glucose and range of glucose. GTD of glucose >150 and glucose >180 also had a high-predictive power for poor outcome (areas under the ROC curve [AUC] = 0.913; 95 % CI, 0.843-0.983 and 0.858; 95 % CI, 0.760-0.956, respectively).
CONCLUSIONS: Continuous collection of glucose recordings is more reliable and accurate than routine discontinuous recordings. Assessing both the duration and the amplitude of the episodes using continuous collection of glucose data helps in better predicting outcomes than the total duration of episodes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 22810485     DOI: 10.1007/s12028-012-9730-0

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  28 in total

1.  Recommendations from the Society of British Neurological Surgeons.

Authors:  J Bartlett; R Kett-White; A D Mendelow; J D Miller; J Pickard; G Teasdale
Journal:  Br J Neurosurg       Date:  1998-08       Impact factor: 1.596

2.  Guidelines for the management of severe traumatic brain injury.

Authors: 
Journal:  J Neurotrauma       Date:  2007       Impact factor: 5.269

Review 3.  Nutritional support.

Authors:  W W Souba
Journal:  N Engl J Med       Date:  1997-01-02       Impact factor: 91.245

4.  Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury.

Authors:  Paul Vespa; Robert Boonyaputthikul; David L McArthur; Chad Miller; Maria Etchepare; Marvin Bergsneider; Thomas Glenn; Neil Martin; David Hovda
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

5.  A novel method of evaluating the impact of secondary brain insults on functional outcomes in traumatic brain-injured patients.

Authors:  Christopher W Barton; J Claude Hemphill; Diane Morabito; Geoffrey Manley
Journal:  Acad Emerg Med       Date:  2005-01       Impact factor: 3.451

6.  Relationship of "dose" of intracranial hypertension to outcome in severe traumatic brain injury.

Authors:  Anne Vik; Torbjørn Nag; Oddrun Anita Fredriksli; Toril Skandsen; Kent Gøran Moen; Kari Schirmer-Mikalsen; Geoffrey T Manley
Journal:  J Neurosurg       Date:  2008-10       Impact factor: 5.115

7.  Mean glucose values predict trauma patient mortality.

Authors:  Wendy L Wahl; Michael Taddonio; Paul M Maggio; Saman Arbabi; Mark R Hemmila
Journal:  J Trauma       Date:  2008-07

8.  Glucose control and mortality in patients with severe traumatic brain injury.

Authors:  Donald E G Griesdale; Marie-Hélène Tremblay; Jonathan McEwen; Dean R Chittock
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

9.  Persistent hyperglycemia in severe traumatic brain injury: an independent predictor of outcome.

Authors:  Ali Salim; Pantelis Hadjizacharia; Joseph Dubose; Carlos Brown; Kenji Inaba; Linda S Chan; Daniel Margulies
Journal:  Am Surg       Date:  2009-01       Impact factor: 0.688

10.  Poor glycemic control is associated with increased mortality in critically ill trauma patients.

Authors:  Stephen C Gale; Corinna Sicoutris; Patrick M Reilly; C William Schwab; Vicente H Gracias
Journal:  Am Surg       Date:  2007-05       Impact factor: 0.688

View more
  4 in total

1.  Effects of Glycemic Level on Outcome of Patients with Traumatic Brain Injury: A Retrospective Cohort Study.

Authors:  Hernando Raphael Alvis-Miranda; Sandy Zuleica Navas-Marrugo; Robert Andrés Velasquez-Loperena; Richard José Adie-Villafañe; Duffay Velasquez-Loperena; Sandra Milena Castellar-Leones; Gabriel Alcala-Cerra; Juan Camilo Pulido-Gutiérrez; Javier Ricardo Rodríguez-Conde; María Fernanda Moreno-Moreno; Andrés M Rubiano; Luis Rafael Moscote-Salazar
Journal:  Bull Emerg Trauma       Date:  2014-04

Review 2.  The gut reaction to traumatic brain injury.

Authors:  Rebeccah J Katzenberger; Barry Ganetzky; David A Wassarman
Journal:  Fly (Austin)       Date:  2015       Impact factor: 2.160

3.  Death following traumatic brain injury in Drosophila is associated with intestinal barrier dysfunction.

Authors:  Rebeccah J Katzenberger; Stanislava Chtarbanova; Stacey A Rimkus; Julie A Fischer; Gulpreet Kaur; Jocelyn M Seppala; Laura C Swanson; Jocelyn E Zajac; Barry Ganetzky; David A Wassarman
Journal:  Elife       Date:  2015-03-05       Impact factor: 8.140

Review 4.  Multimodality monitoring consensus statement: monitoring in emerging economies.

Authors:  Anthony Figaji; Corina Puppo
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.